Aortic & peripheral vascular disease
Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study
Authors' conclusion
This study provides causal evidence for the genetic association between lipid-lowering drugs and AA. Higher gene expression of HMGCR, PCSK9, and CETP increases AA risk. Furthermore, HMGCR inhibitors may link with smaller aortic lumen size.
Study context
- Population
- Publicly available GWAS and expression quantitative trait loci (eQTL) data; aortic aneurysms
- Comparison
- Genetic proxies of lipid-lowering drug targets and aortic aneurysms (AA)
- Outcome
- Aortic aneurysm (AA)
Methodological detailsdrug-target Mendelian randomization, GWAS and eQTL data
- Drug-target Mendelian randomization
- GWAS and eQTL data
Main finding
As reported in the abstract
AA risk
Odds ratio (95% CI)P value
HMGCRhigher expression
1.58(1.20–2.09)
P = 1.20 × 10-03PCSK9suggestive
1.34(1.10–1.63)
P = 3.07 × 10-03CETPsuggestive
1.38(1.06–1.80)
P = 1.47 × 10-02Further findings
Aortic lumen size (HMGCR)
| OR (95% CI) | P value | ||
|---|---|---|---|
| HMGCRAortic maximum area | 1.28 (1.13–1.46) | P = 1.48 × 10-04 | |
| HMGCRAortic minimum area | 1.26 (1.21–1.42) | P = 1.78 × 10-04 | |
| 0.512Odds ratio (log scale) |
Original publication
Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study. Eur J Prev Cardiol. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →